Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...

Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, ...

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

and inactivating integrated HBV DNA. Precision plans to share detailed clinical data throughout 2025. HC Wainwright analyst Patrick Trucchio reiterates Precision BioSciences with a Buy and ...

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA ...

After hours: February 20 at 6:46:07 PM EST Loading Chart for DTIL ...

富马酸丙酚替诺福韦（Tenofovir Alafenamide Fumarate，TAF）应运而生，它在安全性方面表现更优，尤其是在肾脏和骨骼毒性方面有明显改善 ，逐渐受到广泛关注。与此同时，韩国自主研发的马来酸贝西福韦二吡呋酯（Besifovir Dipivoxil Maleate，BSV）也崭露头角。BSV 在病毒学应答、血清学应答以及实验室指标改善等方面，与现有一线疗法效果相当 ...